Opthea Limited (NASDAQ:OPT – Get Free Report) shares saw strong trading volume on Friday . 84,166 shares changed hands during trading, an increase of 204% from the previous session’s volume of 27,659 shares.The stock last traded at $4.87 and had previously closed at $4.60.
Analyst Ratings Changes
Separately, Canaccord Genuity Group upgraded Opthea to a “strong-buy” rating in a report on Tuesday, December 17th.
Opthea Trading Up 5.8 %
Institutional Trading of Opthea
An institutional investor recently bought a new position in Opthea stock. Twin Lakes Capital Management LLC purchased a new position in shares of Opthea Limited (NASDAQ:OPT – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 19,806 shares of the company’s stock, valued at approximately $81,000. 55.95% of the stock is owned by hedge funds and other institutional investors.
Opthea Company Profile
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
See Also
- Five stocks we like better than Opthea
- How to Calculate Stock Profit
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What Does Downgrade Mean in Investing?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- What is the Dogs of the Dow Strategy? Overview and Examples
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
